Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle-mediated infection in humanized liver chimeric mouse models.

Science advances·2026
Same author

A CRISPR-based genome-wide loss-of-function screen defines a role of host metabolism in regulating hepatitis B virus infection.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

A genome-wide siRNA screen identifies previously unknown proviral and antiviral host factors in HBV infection.

Journal of hepatology·2025
Same author

Targets of protective immunity and opportunities in hepatitis C virus vaccine development.

Nature reviews. Immunology·2025
Same author

Structural studies of the IFNλ4 receptor complex using cryoEM enabled by protein engineering.

Nature communications·2025
Same author

Hepatitis B virus genotypes A1 and A2 have distinct replication phenotypes due to polymorphisms in the HBx gene.

PLoS pathogens·2025

Related Experiment Video

Updated: May 9, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Current progress in development of hepatitis C virus vaccines.

T Jake Liang1

  • 1Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health, Bethesda, Maryland, USA. jliang@nih.gov

Nature Medicine
|July 10, 2013
PubMed
Summary

Developing a preventive vaccine for hepatitis C virus (HCV) is challenging due to viral diversity and host immune response. Research focuses on understanding immunity to create effective HCV vaccine candidates.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Experiment Videos

Last Updated: May 9, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) remains a significant global health concern, with effective treatments available but no preventive vaccine.
  • Key challenges include HCV's genetic diversity, persistence mechanisms, and the host's limited immune response.
  • Lack of suitable model systems impedes vaccine development efforts.

Purpose of the Study:

  • To outline strategies for developing a potent and broadly protective hepatitis C vaccine.
  • To highlight the importance of understanding virus-host interactions and protective immunity.
  • To guide the development of vaccine candidates targeting both humoral and cellular immunity.

Main Methods:

  • Reviewing advances in understanding hepatitis C virus-host interactions and protective immunity.
  • Evaluating various approaches for generating and testing viral immunogens.
  • Analyzing the success of vaccine candidates in preclinical models and clinical trials.

Main Results:

  • Significant progress has been made in understanding protective immunity against HCV.
  • Multiple vaccine candidates targeting humoral and cellular immunity are under investigation.
  • Some candidates have shown promise in chimpanzee models and advanced to clinical trials.

Conclusions:

  • Developing an effective hepatitis C vaccine requires a comprehensive approach.
  • Innovative vaccine technologies and rigorous trial designs are crucial for success.
  • Addressing viral diversity and host immune response are key to achieving vaccine efficacy.